Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs VanEck Video Gaming and eSports ETF (ESPO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs VanEck Video Gaming and eSports ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $289.6 (market cap $39.89B), while VanEck Video Gaming and eSports ETF trades at $91.73. The key difference: VanEck Video Gaming and eSports ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | ESPO | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Sector/Thematic |
52-Week High | $491.22 | $122.30 |
52-Week Low | $278.09 | $85.25 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
ESPO trades at $92.35, down 0.52% on the day, with a bullish technical signal driven by moving averages. The ETF's focus on video gaming and esports capitalizes on digital entertainment growth, supported by institutional accumulation. Key resistance lies near $93, with RSI levels indicating potential overbought conditions.
Outlook remains positive due to AI-driven profit potential in gaming, though high RSI suggests near-term consolidation risk. Investors benefit from exposure to a high-growth sector, but should monitor valuation metrics as financial ratios are currently undisclosed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About VanEck Video Gaming and eSports ETF
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →
